dc.contributor.author |
Hemmati, F
|
|
dc.contributor.author |
Hemmati-Dinarvand, M
|
|
dc.contributor.author |
Karimzade, M
|
|
dc.contributor.author |
Rutkowska, Daria A
|
|
dc.contributor.author |
Eskandari, MH
|
|
dc.contributor.author |
Khanizadeh, S
|
|
dc.contributor.author |
Afsharifar, A
|
|
dc.date.accessioned |
2022-03-07T07:26:44Z |
|
dc.date.available |
2022-03-07T07:26:44Z |
|
dc.date.issued |
2021-11 |
|
dc.identifier.citation |
Hemmati, F., Hemmati-Dinarvand, M., Karimzade, M., Rutkowska, D.A., Eskandari, M., Khanizadeh, S. & Afsharifar, A. 2021. Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2. <i>Biotechnology Letters, 44(1).</i> http://hdl.handle.net/10204/12308 |
en_ZA |
dc.identifier.issn |
1573-6776 |
|
dc.identifier.issn |
0141-5492 |
|
dc.identifier.uri |
DOI: 10.1007/s10529-021-03211-0
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12308
|
|
dc.description.abstract |
After its emergence in late 2019 SARS-CoV-2 was declared a pandemic by the World Health Organization on 11 March 2020 and has claimed more than 2.8 million lives. There has been a massive global effort to develop vaccines against SARS-CoV-2 and the rapid and low cost production of large quantities of vaccine is urgently needed to ensure adequate supply to both developed and developing countries. Virus-like particles (VLPs) are composed of viral antigens that self-assemble into structures that mimic the structure of native viruses but lack the viral genome. Thus they are not only a safer alternative to attenuated or inactivated vaccines but are also able to induce potent cellular and humoral immune responses and can be manufactured recombinantly in expression systems that do not require viral replication. VLPs have successfully been produced in bacteria, yeast, insect and mammalian cell cultures, each production platform with its own advantages and limitations. Plants offer a number of advantages in one production platform, including proper eukaryotic protein modification and assembly, increased safety, low cost, high scalability as well as rapid production speed, a critical factor needed to control outbreaks of potential pandemics. Plant-based VLP-based viral vaccines currently in clinical trials include, amongst others, Hepatitis B virus, Influenza virus and SARS-CoV-2 vaccines. Here we discuss the importance of plants as a next generation expression system for the fast, scalable and low cost production of VLP-based vaccines. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://europepmc.org/article/med/34837582 |
en_US |
dc.source |
Biotechnology Letters, 44(1) |
en_US |
dc.subject |
Coronavirus |
en_US |
dc.subject |
SARS-CoV-2 vaccine |
en_US |
dc.subject |
Virus-like particles |
en_US |
dc.subject |
VLPs |
en_US |
dc.subject |
Plant-based VLP-based viral vaccines |
en_US |
dc.title |
Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2 |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
13 |
en_US |
dc.description.note |
Copyright: The Author(s), under exclusive licence to Springer Nature B.V. 2021. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://europepmc.org/article/med/34837582 |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Vetnry Mol Diagnostics and Vac |
en_US |
dc.identifier.apacitation |
Hemmati, F., Hemmati-Dinarvand, M., Karimzade, M., Rutkowska, D. A., Eskandari, M., Khanizadeh, S., & Afsharifar, A. (2021). Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2. <i>Biotechnology Letters, 44(1)</i>, http://hdl.handle.net/10204/12308 |
en_ZA |
dc.identifier.chicagocitation |
Hemmati, F, M Hemmati-Dinarvand, M Karimzade, Daria A Rutkowska, MH Eskandari, S Khanizadeh, and A Afsharifar "Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2." <i>Biotechnology Letters, 44(1)</i> (2021) http://hdl.handle.net/10204/12308 |
en_ZA |
dc.identifier.vancouvercitation |
Hemmati F, Hemmati-Dinarvand M, Karimzade M, Rutkowska DA, Eskandari M, Khanizadeh S, et al. Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2. Biotechnology Letters, 44(1). 2021; http://hdl.handle.net/10204/12308. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Hemmati, F
AU - Hemmati-Dinarvand, M
AU - Karimzade, M
AU - Rutkowska, Daria A
AU - Eskandari, MH
AU - Khanizadeh, S
AU - Afsharifar, A
AB - After its emergence in late 2019 SARS-CoV-2 was declared a pandemic by the World Health Organization on 11 March 2020 and has claimed more than 2.8 million lives. There has been a massive global effort to develop vaccines against SARS-CoV-2 and the rapid and low cost production of large quantities of vaccine is urgently needed to ensure adequate supply to both developed and developing countries. Virus-like particles (VLPs) are composed of viral antigens that self-assemble into structures that mimic the structure of native viruses but lack the viral genome. Thus they are not only a safer alternative to attenuated or inactivated vaccines but are also able to induce potent cellular and humoral immune responses and can be manufactured recombinantly in expression systems that do not require viral replication. VLPs have successfully been produced in bacteria, yeast, insect and mammalian cell cultures, each production platform with its own advantages and limitations. Plants offer a number of advantages in one production platform, including proper eukaryotic protein modification and assembly, increased safety, low cost, high scalability as well as rapid production speed, a critical factor needed to control outbreaks of potential pandemics. Plant-based VLP-based viral vaccines currently in clinical trials include, amongst others, Hepatitis B virus, Influenza virus and SARS-CoV-2 vaccines. Here we discuss the importance of plants as a next generation expression system for the fast, scalable and low cost production of VLP-based vaccines.
DA - 2021-11
DB - ResearchSpace
DP - CSIR
J1 - Biotechnology Letters, 44(1)
KW - Coronavirus
KW - SARS-CoV-2 vaccine
KW - Virus-like particles
KW - VLPs
KW - Plant-based VLP-based viral vaccines
LK - https://researchspace.csir.co.za
PY - 2021
SM - 1573-6776
SM - 0141-5492
T1 - Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2
TI - Plant-derived VLP: A worthy platform to produce vaccine against SARS-CoV-2
UR - http://hdl.handle.net/10204/12308
ER -
|
en_ZA |
dc.identifier.worklist |
25378 |
en_US |